1. Home
  2. SAMG vs PBYI Comparison

SAMG vs PBYI Comparison

Compare SAMG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAMG
  • PBYI
  • Stock Information
  • Founded
  • SAMG 2002
  • PBYI 2010
  • Country
  • SAMG United States
  • PBYI United States
  • Employees
  • SAMG N/A
  • PBYI N/A
  • Industry
  • SAMG Investment Managers
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAMG Finance
  • PBYI Health Care
  • Exchange
  • SAMG Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • SAMG 170.2M
  • PBYI 145.3M
  • IPO Year
  • SAMG 2013
  • PBYI N/A
  • Fundamental
  • Price
  • SAMG $18.41
  • PBYI $2.91
  • Analyst Decision
  • SAMG
  • PBYI Strong Buy
  • Analyst Count
  • SAMG 0
  • PBYI 1
  • Target Price
  • SAMG N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • SAMG 17.4K
  • PBYI 288.9K
  • Earning Date
  • SAMG 03-06-2025
  • PBYI 02-27-2025
  • Dividend Yield
  • SAMG 4.21%
  • PBYI N/A
  • EPS Growth
  • SAMG N/A
  • PBYI 492.79
  • EPS
  • SAMG 0.79
  • PBYI 0.47
  • Revenue
  • SAMG $120,231,000.00
  • PBYI $243,569,000.00
  • Revenue This Year
  • SAMG $7.36
  • PBYI N/A
  • Revenue Next Year
  • SAMG $6.62
  • PBYI N/A
  • P/E Ratio
  • SAMG $24.03
  • PBYI $6.24
  • Revenue Growth
  • SAMG 2.45
  • PBYI 6.30
  • 52 Week Low
  • SAMG $13.93
  • PBYI $2.23
  • 52 Week High
  • SAMG $19.20
  • PBYI $7.15
  • Technical
  • Relative Strength Index (RSI)
  • SAMG 50.45
  • PBYI 48.76
  • Support Level
  • SAMG $17.86
  • PBYI $2.69
  • Resistance Level
  • SAMG $19.04
  • PBYI $2.98
  • Average True Range (ATR)
  • SAMG 0.43
  • PBYI 0.12
  • MACD
  • SAMG 0.02
  • PBYI 0.01
  • Stochastic Oscillator
  • SAMG 46.61
  • PBYI 58.11

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: